Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Bayer calcium chews

This article was originally published in The Tan Sheet

Executive Summary

Flintstones and One-A-Day Scooby Doo! Bone Building Calcium Chews, on shelves now, "provide as much calcium as two 6.5 oz. glasses of milk, plus vitamin D to help absorb calcium," Bayer says. Recommended for children ages four to 12, chocolate-flavored chews are available in 45-count containers, sell for about $8.99. Print ads are appearing in October publications, TV spots broke Sept. 4, Bayer notes. Packaging claims: "According to the American Academy of Pediatrics, calcium intake in childhood may be a critical factor in preventing osteoporosis later in life"...

You may also be interested in...



Boehringer Ingelheim Overtakes Bayer As Germany’s Biggest Pharma Company

The privately owned company is searching for a successor to Jardiance, while the outcome of US Inflation Reduction Act talks on price cuts to the blockbuster will be revealed in September.

Synthekine Joins Quest To Tame IL-2 In Cancer Therapies

First clinical data from Synthekine’s IL-2 candidate and that ofrivalsMedicennawere presented at the AACR, suggesting there’s life in the modality yet.

Swisse Supplements Take Bigger Slice Of Chinese Market

Australian-heritage Swisse grew its share of China's supplements market in 2023 by delivering tailored products to an increasingly health conscious population.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS094606

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel